Generation of Reactive T Cells Based on Tumor Whole Cell Antigen Nanovaccines

NCT07239544 · tracked via the Priya Life Science China tracker

Sponsor

The First Affiliated Hospital of Soochow University

Phase

Observational

Started

2025-07-10

Last updated

2025-11-20

Condition(s) studied

Lung Cancer (NSCLC)

Investigational drug(s) / intervention(s)

observational study

observational study: observational study:Evaluate the broad-spectrum coverage of xenogeneic hybrid lung cancer antigens (including patient tissues and cell lines), and develop a universal whole-cell antigen nanodelivery system to replace autologous tumor-derived preparation

Study summary

Tumor-reactive T cells are generated based on the tumor full antigen nanovaccine and the tumor-reactive T cells are reinjected for autologous therapy to provide the optimal treatment plan for clinical patients.

Eligibility

Sex

ALL

Min age

18 Years

Max age

90 Years

Healthy volunteers

Inclusion Criteria: \- a.Freshly frozen tumor tissue samples of at least 0.5cm\*0.5cm in length and diameter were obtained from patients with histologically confirmed primary non-small cell lung cancer (NSCLC) who underwent surgical resection. b. HLA typing must match the preselected subtypes: prioritize common subtypes such as HLA-A\*0201 and HLA-A\*2402 to ensure standardized subsequent T-cell response evaluation. Exclusion Criteria: \- a.History of active autoimmune diseases: such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, etc., to avoid vaccine-induced immune storm. b. Previous immunotherapy: including PD-1/L1 inhibitors, CTLA-4 inhibitors, cancer vaccines, or other cellular therapies within 6 months, with treatment interference excluded.

Primary outcome measure(s)

Tumor reactive cells — 6 month
To evaluate the antitumor effects of tumor-reactive T cells in human 3D lung cancer organoids, and to elucidate the in vivo migration and localization, tumor infiltration characteristics, and survival dynamics of reinfused tumor-reactive T cells, thereby clarifying their role and translational potential in biological therapy.

Trial sites (1)

Facility	City	Region	Status
Soochow university	Suzhou	Jiangsu

More The First Affiliated Hospital of Soochow University trials in China

Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia Recruiting

Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy Recruiting

Olverembatinib for FGFR1-rearranged Neoplasms Recruiting

A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia Recruiting

N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic Microangiopathy Active, not recruiting

Other trials for the same condition

Application Research of Methylation Markers in Early-stage Lung Cancer Patients Treated With Co-ablation System Therapy Recruiting

Analysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor Therapy Starting soon

A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer Recruiting

Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients Recruiting

Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501） Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07239544 on ClinicalTrials.gov ↗ ← All trials in China